Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Patient Risk Stratification Market Size Changed, over the years?

Recent years have seen significant expansion in the patient risk stratification market size. The increase from $2.15 billion in 2024 to $2.82 billion in 2025 represents a compound annual growth rate (CAGR) of 31.3%. Factors contributing to this growth during the historical period include the widespread adoption of digitization, heightened risk, an aging population, increased instances of medical errors, and the growing use of electronic health records (EHR).

How Much Will the Patient Risk Stratification Market Be Worth in 2029?

There’s an anticipated surge in the patient risk stratification market size in the subsequent years. It’s predicted to amplify to $8.30 billion by 2029, with a compound annual growth rate (CAGR) of 31.0%. The growth during the projected timeline can be linked to the expanding middle class and health insurance, amplified presence of chronic diseases, widespread use of predictive analytics, heightened focus on social determinants of health (SDOH), and the escalated application of technology. Prominent trends in the forecast duration encompass enhancements in analytics, artificial intelligence (AI), machine learning, technological advancement, leading-edge tools, evolving technology in healthcare, wearable tech, and remote patient monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20917&type=smp

Which is the Largest Company in the Patient Risk Stratification Market?

Major companies operating in the patient risk stratification market are Bristol-Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Sales Force Inc., Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Adobe Inc., Persistent Systems, NextGen Healthcare Inc., Health Catalyst, Freenome, Strive Health, Medeanalytics Inc., American Academy of Family Physicians, Lightbeam Health Solutions, Graphnet Health Ltd., Innova Medical Group Inc., Equipo Health Inc., Epic Systems Corporation

What Are the Main Market Drivers in the Patient Risk Stratification Industry?

The escalating prevalence of persistent conditions is predicted to drive the expansion of the patient risk stratification market. These chronic diseases are enduring health ailments that last for protracted periods, usually exceeding three months. The increasing impact of chronic diseases can be linked to factors such as an aging demographic, unhealthy lifestyles, urbanization, environmental factors, constrained healthcare access, economic disparities, and elevated stress levels. Patient risk stratification enables the identification of individuals at varying risk tiers for chronic diseases, facilitating personalized healthcare, early intervention, efficient resource distribution, and enhanced health results. For example, in January 2023, the National Center for Biotechnology Information (NCBI), a U.S.-based National Library of Medicine, projected that the count of individuals aged 50 and over with a minimum of one chronic disease is expected to surge by 99.5%, ascending from 71.522 million in 2020 to 142.66 million by 2050. Also, the World Health Organization (WHO) 2022 Highlights, a Switzerland-based intergovernmental health body, reported in September 2022 that globally 74% of all deaths are attributed to chronic diseases, equating to 41 million deaths annually. Breakdown of these statistics reflects that cardiovascular diseases are responsible for 17.9 million deaths, cancer for 9.3 million, chronic respiratory diseases for 4.1 million, and diabetes for 2.0 million deaths. Hence, the escalating prevalence of chronic diseases underpins the expansion of the patient risk stratification market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20917&type=smp

How Is the Patient Risk Stratification Market Segments Structured?

The patient risk stratification market covered in this report is segmented –

1) By Type: Predictive Risk Stratification Model, Retrospective Risk Stratification Model, Prospective Risk Stratification Model, Concurrent Risk Stratification Model

2) By Component: Software, Services

3) By Delivery Model: On-Premise, Cloud-Based

4) By Application: Risk Adjustment, Clinical Workflow, Revenue Cycle Management, Other Applications

5) By End User: Healthcare Providers, Healthcare Payers, Other End Users

Subsegments:

1) By Predictive Risk Stratification Model: Machine Learning-Based Predictive Models, Statistical Predictive Models, AI-Powered Predictive Models

2) By Retrospective Risk Stratification Model: Historical Data-Based Risk Models, Data Mining Retrospective Models

3) By Prospective Risk Stratification Model: Longitudinal Cohort-Based Models, Real-Time Risk Assessment Models

4) By Concurrent Risk Stratification Model: In-Hospital Risk Assessment Models, Real-Time Clinical Decision Support Models

What Strategic Trends Are Transforming the Patient Risk Stratification Market?

Firms that are influential players in the realm of patient risk stratification are honing their focus on revolutionary advancements in health technology. This includes the application of Artificial Intelligence (AI) in disease screening, which is instrumental in facilitating early detection, aiding improved rounds of patient outcomes, and slumping expenses in healthcare. This is achieved by providing more precise risk evaluations and tailoring treatment strategies. AI is employed for disease screening by using meticulous algorithms and machine learning for inspecting medical records. This helps to identify diseases at their genesis, while also bolstering the accuracy of diagnoses, by rapidly scrutinizing a significant bulk of data. A salient example of this occurred in May 2024 when the Canadian healthcare enterprise WELL Health Technologies Corporation, along with its affiliate company HEALWELL AI, who specialize in AI and data examination for preemptive care, unveiled the WELL AI Decision Support (WAIDS). This innovation is targeted specifically at rare diseases but now also includes screening for chronic disorders like kidney disease, hypertension, and diabetes. It boasts the capacity to identify over 100 diseases and offers risk stratification. This aides medical professionals in pinpointing gaps in patient care and gives them immediate access to crucial data at the location of patient care.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/patient-risk-stratification-global-market-report

Which Global Regions Offer the Highest Growth in the Patient Risk Stratification Market?

North America was the largest region in the patient risk stratification market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient risk stratification market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20917

This Report Delivers Insight On:

1. How big is the patient risk stratification market, and how is it changing globally?

2. Who are the major companies in the patient risk stratification market, and how are they performing?

3. What are the key opportunities and risks in the patient risk stratification market right now?

4. Which products or customer segments are growing the most in the patient risk stratification market?

5. What factors are helping or slowing down the growth of the patient risk stratification market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model